As stated previously, studies of other mTORC1/2 inhibitors in advanced RCC have also reported issues with tolerability.25,27 The most frequent TEAEs reported with sapanisertib or sapanisertib plus TAK-117 were nonetheless consistent with previous studies of single-agent sapanisertib16,17,30 and were generally in line with the pharmacodynamic mechanism of mTOR and PI3K inhibitors. This evidence concerns the gene MTOR and renal cell carcinoma.